Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism-Journal of Psychiatry and Brain Science-CSCIED科技核心评价数据库-手机版

Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism

Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism

ES评分 0 浏览量：455 下载量：0

全文阅读下载引用收藏

DOI	10.20900/jpbs.20190013
刊名	Journal of Psychiatry and Brain Science JPBS
年，卷(期)	2019, 4(4)
作者	Laura N. Castellani,Kenya A. Costa-Dookhan,William B. McIntyre,David C. Wright,Stephanie A. Flowers,Margaret K.Hahn*,Kristen M. Ward,
作者单位
Abstract	Antipsychotic (AP) medications are associated with an increased risk of developing metabolic side effects including weight gain, type 2 diabetes (T2D), dyslipidemia, and hypertension. In the majority of clinical studies, females on APs are noted to gain more weight, and are more likely to be diagnosed with metabolic syndrome when compared to males. However, the data is less clear when comparing sex disparities associated with other specific AP-induced metabolic risk factors. Accumulating evidence has demonstrated a role for AP-induced adipose tissue accumulation as well as whole body glucose dysregulation in male models that is independent of changes in body weight. The purpose of this narrative review is to explore the susceptibility of males and females to changes in adiposity and glucose metabolism across clinical and preclinical models of AP treatment. It is important that future research examining AP-induced metabolic side effects analyzes outcomes by sex to help clarify risk and identify the mechanisms of adverse event development to improve safe prescribing of medications.
KeyWord	visceral adipose tissue; insulin resistance; metabolic side effects; sex differences; antipsychotics
基金项目
页码	-

参考文献
相关文献

1.Konstantinidis A, Papageorgiou K, Grohmann R, Horvath A, Engel R, Kasper S. Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. Int J Neuropsychopharmacol. 2012;15:449-57.

2.Morin AK. Off-label use of atypical antipsychotic agents for treatment of insomnia. Ment Heal Clin. 2014;4:65-72.

3.Harrison JN, Cluxton-Keller F, Gross D. Antipsychotic medication prescribing trends in children and adolescents. J Pediatr Health Care. 2012;26:139-45.

4.Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C. Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009;19:629-635.

5.Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085-97.

6.Bergman RN, Ader M. Atypical Antipsychotics and Glucose Homeostasis. J Clin Psychiatry. 2005;66:504-14.

7.Gibson K, Cde R, Dietitian S. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Available from: http://guidelines.diabetes.ca/docs/CPG-2018-full-EN.pdf. Accessed 2019 Aug 12.

8.Oriot P, Feys J-L, Mertens de Wilmars S, Misson A, Ayache L, Fagnart O, et al. Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. Diabetes Metab. 2008;34:490-6.

9.Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, et al. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2016;73:247-59.

10.Rajkumar AP, Horsdal HT, Wimberley T, Cohen D, Mors O, Børglum AD, et al. Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study. Am J Psychiatry. 2017;174:686-94.

11.Hahn MK, Wolever TMS, Arenovich T, Teo C, Giacca A, Powell V, et al. Acute Effects of Single-Dose Olanzapine on Metabolic, Endocrine, and Inflammatory Markers in Healthy Controls. J Clin Psychopharmacol. 2013;33:740-6.

12.Albaugh VL, Singareddy R, Mauger D, Lynch CJ. A Double Blind, Placebo-Controlled, Randomized Crossover Study of the Acute Metabolic Effects of Olanzapine in Healthy Volunteers. PLoS One. 2011;6(8):e22662. doi: 10.1371/journal.pone.0022662

13.Fell MJ, Anjum N, Dickinson K, Marshall KM, Peltola LM, Vickers S, et al. The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology. 2007;194:221-31.

14.Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM, et al. Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology. 2005;182:220-31.

15.Minet-Ringuet J, Even PC, Guesdon B, Tomé D, de Beaurepaire R. Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection. Behav Brain Res. 2005;163:204-11.

16.Victoriano M, Hermier D, Even PC, Fromentin G, Huneau J-F, Tomé D, et al. Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats. Psychopharmacology. 2009;206:167-76.

17.Lau SL, Muir C, Assur Y, Beach R, Tran B, Bartrop R, et al. Predicting Weight Gain in Patients Treated With Clozapine. J Clin Psychopharmacol. 2016;36:120-4.

18.Covell NH, Weissman EM, Essock SM. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophr Bull. 2004;30:229-40.

19.Xiang Y-T, Wang C-Y, Si T-M, Lee EH, He YL, Ungvari GS, et al. Sex Differences in Use of Psychotropic Drugs and Drug-Induced Side Effects in Schizophrenia Patients: Findings of the Research on Asia Psychotropic Prescription (REAP) Studies. Aust New Zeal J Psychiatry. 2011;45:193-8.

20.Haack S, Seeringer A, Thürmann PA, Becker T, Kirchheiner J. Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics. 2009;10:1511-1526.

21.Hakko H, Komulainen MT, Koponen H, Saari K, Laitinen J, Järvelin MR, et al. Are females at special risk of obesity if they become psychotic? The longitudinal Northern Finland 1966 Birth Cohort Study. Schizophr Res. 2006;84:15-9.

22.Verma S, Liew A, Subramaniam M, Poon LY. Effect of Treatment on Weight Gain and Metabolic Abnormalities in Patients with First-Episode Psychosis. Aust New Zeal J Psychiatry. 2009;43:812-7.

23.Lee E, Leung C-M, Wong E. Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. J Clin Psychiatry. 2004;65:864-6.

24.Lipkovich I, Jacobson JG, Caldwell C, Hoffmann VP, Kryzhanovskaya L, Beasley CM. Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials. Psychopharmacol Bull. 2009;42:23-39.

25.Attux C, Quintana MI, Chaves AC. Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up. Rev Bras Psiquiatr. 2007;29:346-9.

26.Taylor JH, Jakubovski E, Gabriel D, Bloch MH. Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study. J Child Adolesc Psychopharmacol. 2018;28:474-84.

27.Sušilová L, Češková E, Hampel D, Sušil A7, Šimůnek J. Changes in BMI in hospitalized patients during treatment with antipsychotics, depending on gender and other factors. Int J Psychiatry Clin Pract. 2017;21:112-7.

28.Lane H-Y, Liu Y-C, Huang C-L, Chang YC, Wu PL, Lu CT, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol. 2006;26:128-34.

29.Konarzewska B, Stefańska E, Wendołowicz A, Cwalina U, Golonko A, Małus A, et al. Visceral obesity in normal-weight patients suffering from chronic schizophrenia. BMC Psychiatry. 2014;14:35.

30.Sugawara N, Yasui-Furukori N, Tsuchimine S, Fujii A, Sato Y, Saito M, et al. Body composition in patients with schizophrenia: Comparison with healthy controls. Ann Gen Psychiatry. 2012;11:11.

31.Zhang Z-J, Yao Z-J, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004;184:58-62.

32.Satoh M, Sakuda H, Kobayashi T, Kataoka T, Nakao F, Turale S. Comparison of the body fluid levels in healthy individuals and those with schizophrenia in Japan: using the bioelectrical impedance method. Nurs Health Sci. 2007;9:177-84.

33.Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, Halle B, et al. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring). 2006;14:36-51.

34.Arjona A, Zhang SX, Adamson B, Wurtman RJ. An animal model of antipsychotic-induced weight gain. Behav Brain Res. 2004;152:121-7.

35.Cooper GD, Pickavance LC, Wilding JPH, Halford JC, Goudie AJ. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl). 2005;181:80-9.

36.Cooper GD, Harrold JA, Halford JCG, Goudie AJ. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: Implications for animal models of antipsychotic-induced weight gain. Prog Neuro-Psychopharmacology Biol Psychiatry. 2008;32:428-36.

37.Ersland KM, Myrmel LS, Fjære E, Berge RK, Madsen L, Steen VM, et al. One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects. Int J Neuropsychopharmacol. 2019;22:358-69.

38.Fell MJ, Marshall KM, Williams J, Neill JC. Effects of the Atypical Antipsychotic Olanzapine on Reproductive Function and Weight Gain in Female Rats. J Psychopharmacol. 2004;18:14955.

39.Goudie AJ, Smith JA, Halford JCG. Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol. 2002;16:291-6.

40.Hu Y, Young AJ, Ehli EA, Nowotny D, Davies PS, Droke EA, et al. Metformin and Berberine Prevent Olanzapine-Induced Weight Gain in Rats. PLoS One. 2014;9:e93310.

41.Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res. 2008;103:94-103.

42.Mann S, Chintoh A, Giacca A, Fletcher P, Nobrega J, Hahn M, et al. Chronic olanzapine administration in rats: Effect of route of administration on weight, food intake and body composition. Pharmacol Biochem Behav. 2013;103:717-22.

43.Pouzet B, Mow T, Kreilgaard M, Velschow S. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav. 2003;75:133-40.

44.Skrede S, Martins L, Berge RK, Steen VM, López M, Fernø J. Olanzapine depot formulation in rat: A step forward in modelling antipsychotic-induced metabolic adverse effects. Int J Neuropsychopharmacol. 2014;17:91-104.

45.Skrede S, Fernø J, Vázquez MJ, Fjær S, Pavlin T, Lunder N, et al. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol. 2012;15:163-79.

46.Skrede S, González-García I, Martins L, Berge RK, Nogueiras R, Tena-Sempere M, et al. Lack of Ovarian Secretions Reverts the Anabolic Action of Olanzapine in Female Rats. Int J Neuropsychopharmacol. 2017;20:1005-12.

47.Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 2005;54:862-71.

48.Albaugh VL, Judson JG, She P, Lang CH, Maresca KP, Joyal JL, et al. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry. 2011;16:569-81.

49.Baptista T, Mata A, Teneud L, de Quijada M, Han HW, Hernández L. Effects of long-term administration of clozapine on body weight and food intake in rats. Pharmacol Biochem Behav. 1993;45:51-4.

50.Cooper GD, Pickavance LC, Wilding JPH, Harrold JA, Halford JC, Goudie AJ. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol. 2007;21:405-13.

51.Ferno J, Ersland KM, Duus IH, González-García I, Fossan KO, Berge RK, et al. Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain. Eur Neuropsychopharmacol. 2015;25:923-32.

52.Minet-Ringuet J, Even PC, Lacroix M, Tomé D, de Beaurepaire R. A model for antipsychotic-induced obesity in the male rat. Psychopharmacology (Berl). 2006;187:447-54.

53.Minet-Ringuet J, Even PC, Goubern M, Tomé D, de Beaurepaire R. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite. 2006;46:254-62.

54.Smith GC, Chaussade C, Vickers M, Jensen J, Shepherd PR. Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia. 2008;51:2309-17.

55.Smith GC, Vickers MH, Cognard E, Shepherd PR. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. Schizophr Res. 2009;115:30-40.

56.Fernø J, Varela L, Skrede S, Vázquez MJ, Nogueiras R, Diéguez C, et al. Olanzapine-Induced Hyperphagia and Weight Gain Associate with Orexigenic Hypothalamic Neuropeptide Signaling without Concomitant AMPK Phosphorylation. PLoS One. 2011;6:e20571.

57.Ersland KM, Skrede S, Røst TH, Berge RK, Steen VM. Antipsychotic-induced metabolic effects in the female rat: Direct comparison between long-acting injections of risperidone and olanzapine. J Psychopharmacol. 2015;29:1280-9.

58.Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther. 2003;305:625-31.

59.Coccurello R, Brina D, Caprioli A, Conti R, Ghirardi O, Schepis F, et al. 30 Days of Continuous Olanzapine Infusion Determines Energy Imbalance, Glucose Intolerance, Insulin Resistance, and Dyslipidemia in Mice. J Clin Psychopharmacol. 2009;29:576-83.

60.Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2007;32:289-97.

61.Townsend LK, Peppler WT, Bush ND, Wright DC. Obesity exacerbates the acute metabolic side effects of olanzapine. Psychoneuroendocrinology. 2018;88:121-8.

62.Després J-P. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012;126:1301-13.

63.Sironi AM, Petz R, De Marchi D, Buzzigoli E, Ciociaro D, Positano V, et al. Impact of increased visceral and cardiac fat on cardiometabolic risk and disease. Diabet Med. 2012;29:622-7.

64.Gruzdeva O, Borodkina D, Uchasova E, Dyleva Y, Barbarash O. Localization of fat depots and cardiovascular risk. Lipids Health Dis. 2018;17:218.

65.Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci. 2004;74:1999-2008.

66.Nilsson BM, Forslund AH, Olsson RM, Hambraeus L, Wiesel FA. Differences in resting energy expenditure and body composition between patients with schizophrenia and healthy controls. Acta Psychiatr Scand. 2006;114:27-35.

67.Saarni SE, Saarni SI, Fogelholm M, Heliövaara M, Perälä J, Suvisaari J, et al. Body composition in psychotic disorders: a general population survey. Psychol Med. 2009;39:801-10.

68.Kraal AZ, Ward KM, Ellingrod VL. Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders. Psychopharmacol Bull. 2017;47:8-21.

69.Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes. 2013;62:3232-40.

70.Sowell MO, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg HO, Breier A, et al. Hyperglycemic Clamp Assessment of Insulin Secretory Responses in Normal Subjects Treated with Olanzapine, Risperidone, or Placebo. J Clin Endocrinol Metab. 2002;87:2918-23.

71.Sowell M, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S, et al. Evaluation of Insulin Sensitivity in Healthy Volunteers Treated with Olanzapine, Risperidone, or Placebo: A Prospective, Randomized Study Using the Two-Step Hyperinsulinemic, Euglycemic Clamp. J Clin Endocrinol Metab. 2003;88:5875-80.

72.Kopf D, Gilles M, Paslakis G, Medlin F, Lederbogen F, Lehnert H, et al. Insulin Secretion and Sensitivity after Single-Dose Amisulpride, Olanzapine or Placebo in Young Male Subjects: Double Blind, Cross-Over Glucose Clamp Study. Pharmacopsychiatry. 2012;45:223-8.

73.Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, Sauermann R, et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology. 2008;33:1633-41.

74.Vidarsdottir S, Roelfsema F, Frolich M, Pijl H. Olanzapine shifts the temporal relationship between the daily acrophase of serum prolactin and cortisol concentrations rhythm in healthy men. Psychoneuroendocrinology. 2009;34:705-12.

75.Vidarsdottir S, de Leeuw van Weenen JE, Frölich M, Roelfsema F, Romijn JA, Pijl H. Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab. 2010;95:118-25.

76.Boyda H, Procyshyn R, Tse L, Hawkes E, Jin CH, Pang CC, et al. Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. J Psychiatry Neurosci. 2012;37:407-15.

77.Boyda HN, Procyshyn RM, Asiri Y, Wu C, Wang CK, Lo R, et al. Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;48:170-6.

78.Jassim G, Skrede S, Vázquez MJ, Wergedal H, Vik-Mo AO, Lunder N, et al. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology. 2012;219:783-94.

79.Martins PJF, Haas M, Obici S. Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes. 2010;59:2418-25.

80.Wu C, Yuen J, Boyda HN, Procyshyn RM, Wang CK, Asiri YI, et al. An Evaluation of the Effects of the Novel Antipsychotic Drug Lurasidone on Glucose Tolerance and Insulin Resistance: A Comparison with Olanzapine. PLoS One. 2014;9:e107116.

81.Albaugh VL, Vary TC, Ilkayeva O, Wenner BR, Maresca KP, Joyal JL, et al. Atypical Antipsychotics Rapidly and Inappropriately Switch Peripheral Fuel Utilization to Lipids, Impairing Metabolic Flexibility in Rodents. Schizophr Bull. 2012;38:153-66.

82.Bush ND, Townsend LK, Wright DC. AICAR Prevents Acute Olanzapine-Induced Disturbances in Glucose Homeostasis. J Pharmacol Exp Ther. 2018;365:526-35.

83.Castellani LN, Peppler WT, Sutton CD, , Whitfield J, Charron MJ, Wright DC. Glucagon receptor knockout mice are protected against acute olanzapine-induced hyperglycemia. Psychoneuroendocrinology. 2017;82:38-45.

84.Castellani LN, Peppler WT, Miotto PM, Bush N, Wright DC. Exercise Protects Against Olanzapine-Induced Hyperglycemia in Male C57BL/6J Mice. Sci Rep. 2018;8:772.

85.Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, Fletcher PJ, et al. Insulin Resistance and Decreased Glucose-Stimulated Insulin Secretion After Acute Olanzapine Administration. J Clin Psychopharmacol. 2008;28:494-9.

86.Chintoh AF, Mann SW, Lam L, Giacca A, Fletcher P, Nobrega J, et al. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr Res. 2009;108:127-33.

87.Girault EM, Alkemade A, Foppen E, Ackermans MT, Fliers E, Kalsbeek A. Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance. PLoS One. 2012;7:e43244.

88.Hahn MK, Chintoh A, Remington G, Teo C, Mann S, Arenovich T, et al. Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: An animal model. Eur Neuropsychopharmacol. 2014;24:448-58.

89.Ikegami M, Ikeda H, Ohashi T, Kai M, Osada M, Kamei A, et al. Olanzapine-Induced Hyperglycemia: Possible Involvement of Histaminergic, Dopaminergic and Adrenergic Functions in the Central Nervous System. Neuroendocrinology. 2013;98:224-32.

90.Ikegami M, Ikeda H, Ishikawa Y, Ohsawa M, Ohashi T, Kai M, et al. Olanzapine induces glucose intolerance through the activation of AMPK in the mouse hypothalamus. Eur J Pharmacol. 2013;718:376-82.

91.Ikegami M, Ikeda H, Ohashi T, Ohsawa M, Ishikawa Y, Kai M, et al. Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5′-monophosphate-activated protein kinase. Diabetes, Obes Metab. 2013;15:1128-35.

92.Klingerman CM, Stipanovic ME, Hajnal A, Lynch CJ. Acute Metabolic Effects of Olanzapine Depend on Dose and Injection Site. Dose Response. 2015;13:1559325815618915.

93.Kowalchuk C, Teo C, Wilson V, Chintoh A, Lam L, Agarwal SM, et al. In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. J Psychiatry Neurosci. 2017;42:424-31.

94.Nagata M, Nakajima M, Ishiwata Y, Takahashi Y, Takahashi H, Negishi K, et al. Mechanism Underlying Induction of Hyperglycemia in Rats by Single Administration of Olanzapine. Biol Pharm Bull. 2016;39:754-61.

95.Castellani LN, Peppler WT, Sutton CD, Whitfield J, Charron MJ, Wright DC. Glucagon receptor knockout mice are protected against acute olanzapine-induced hyperglycemia. Psychoneuroendocrinology. 2017;82:38-45.

96.Hartfield AW, Moore NA, Clifton PG. Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology (Berl). 2003;167:115-22.

97.Cuerda C, Velasco C, Merchán-Naranjo J, García-Peris P, Arango C. The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity. Eur J Clin Nutr. 2014;68:146-52.

98.Sentissi O, Viala A, Bourdel MC, Kaminski F, Bellisle F, Olié JP, et al. Impact of antipsychotic treatments on the motivation to eat: preliminary results in 153 schizophrenic patients. Int Clin Psychopharmacol. 2009;24:257-64.

99.Perry B, Wang Y. Appetite regulation and weight control: the role of gut hormones. Nutr Diabetes. 2012;2:e26.

100.Colley DL, Castonguay TW. Effects of sugar solutions on hypothalamic appetite regulation. Physiol Behav. 2015;139:202-9.

101.Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, et al. Increased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men. Obesity. 2010;18:1646-51.

102.Graham KA, Perkins DO, Edwards LJ, Barrier RC Jr, Lieberman JA, Harp JB. Effect of Olanzapine on Body Composition and Energy Expenditure in Adults With First-Episode Psychosis. Am J Psychiatry. 2005;162:118-23.

103.Berg KE. Comparison of energy expenditure in men and women at rest and during exercise recovery. J Sports Med Phys Fitness. 1991;31:351-6.

104.Santosa S, Khosla S, McCready LK, Jensen MD. Effects of Estrogen and Testosterone on Resting Energy Expenditure in Older Men. Obesity. 2010;18:2392-4.

105.Lord CC, Wyler SC, Wan R, Castorena CM, Ahmed N, Mathew D, et al. The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C. J Clin Invest. 2017;127:3402-6.

106.Castellani LN, Wilkin J, Abela AR, Benarroch L, Ahasan Z, Teo C, et al. Effects of acute olanzapine exposure on central insulin-mediated regulation of whole body fuel selection and feeding. Psychoneuroendocrinology. 2018;98:127-30.

107.Fischer AW, Cannon B, Nedergaard J. Optimal housing temperatures for mice to mimic the thermal environment of humans: An experimental study. Mol Metab. 2018;7:161-70.

108.Gordon CJ. The mouse thermoregulatory system: Its impact on translating biomedical data to humans. Physiol Behav. 2017;179:55-66.

109.Lizcano F, Guzmán G. Estrogen Deficiency and the Origin of Obesity during Menopause. Biomed Res Int. 2014;2014:757461.

110.Mauvais-Jarvis F, Clegg DJ, Hevener AL. The Role of Estrogens in Control of Energy Balance and Glucose Homeostasis. Endocr Rev. 2013;34:309-38.

111.Rettberg JR, Yao J, Brinton RD. Estrogen: A master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol. 2014;35:8-30.

112.Park S, Hong SM, Ahn SH, Kim SH. Olanzapine, not resperidone, exacerbates β-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them. J Psychopharmacol. 2010;24:1105-14.

113.Park S, Hong SM, Ahn ILS, Kim DS, Kim SH. Estrogen Replacement Reverses Olanzapine-Induced Weight Gain and Hepatic Insulin Resistance in Ovariectomized Diabetic Rats. Neuropsychobiology. 2010;61:148-161.

114.Shimizu H, Shimomura Y, Uehara Y, Kobayashi I, Kobayashi S. Involvement of Sex Hormone in Body Weight Gain by Selective D2 Receptor Antagonist Sulpiride. Exp Clin Endocrinol Diabetes. 2009;96:25-29.

115.Fitzgerald PB, Scaffidi A, Morris MJ, de Castella AR, Kulkarni J. The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. Hum Psychopharmacol Clin Exp. 2003;18:551-7.

116.Handgraaf S, Dusaulcy R, Visentin F, Philippe J, Gosmain Y. 17-β Estradiol regulates proglucagon-derived peptide secretion in mouse and human α- and L cells. JCI Insight. 2018. doi: 10.1172/jci.insight.98569.

117.Tiano JP, Mauvais-Jarvis F. Importance of oestrogen receptors to preserve functional β-cell mass in diabetes. Nat Rev Endocrinol. 2012;8:342-51.

118.González-Rodríguez A, Catalán R, Penadés R, Ruiz Cortés V, Torra M, Seeman MV, et al. Antipsychotic Response Worsens With Postmenopausal Duration in Women With Schizophrenia. J Clin Psychopharmacol. 2016;36:580-7.

119.Goldstein JM, Cohen LS, Horton NJ, Lee H, Andersen S, Tohen M, et al. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res. 2002;110:27-37.

120.Weiss U, Marksteiner J, Kemmler G, Saria A, Aichhorn W. Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol. 2005;25:570-4.

121.Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol. 2006;95:136-47.

122.Guo C, Li Q, Tian G, Liu Y, Sun X, Yin Z, et al. Association of age at menopause and type 2 diabetes: A systematic review and dose-response meta-analysis of cohort studies. Prim Care Diabetes. 2019;13:301-9.

123.Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63:280-93.

124.Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48:143-57.

125.Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Clin Pharmacokinet. 1999;37:177-93.

126.Relling M V, Lin J, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2* activities. Clin Pharmacol Ther. 1992;52:643-58.

127.Rasmussen BB, Brøsen K. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit. 1996;18:254-62.

128.Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of Obesity on the Pharmacokinetics of Drugs in Humans. Clin Pharmacokinet. 2010;49:71-87.

129.Maier L, Pruteanu M, Kuhn M, Zeller G2, Telzerow A, Anderson EE, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555:623-8.

130.Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913-6.e7.

131.Küme T, Acar S, Tuhan H, Çatlı G, Anık A, Gürsoy Çalan Ö, et al. The Relationship between Serum Zonulin Level and Clinical and Laboratory Parameters of Childhood Obesity. J Clin Res Pediatr Endocrinol. 2017;9:31-38.

132.Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016;8:42.

133.Stępień M, Stępień A, Wlazeł RN, Paradowski M, Banach M, Rysz J. Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study. Lipids Health Dis. 2014;13:29.

134.Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke J-D, Serino M, et al. Intestinal permeability—a new target for disease prevention and therapy. BMC Gastroenterol. 2014;14:189.

135.Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell. 2001;104:531-43.

136.Morgan AP, Crowley JJ, Nonneman RJ, Quackenbush CR, Miller CN, Ryan A, et al. The Antipsychotic Olanzapine Interacts with the Gut Microbiome to Cause Weight Gain in Mouse. PLoS One. 2014;9:e115225.

137.Bahr SM, Weidemann BJ, Castro AN, Walsh JW, deLeon O, Burnett CM, et al. Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. EBioMedicine. 2015;2:1725-34.

138.Bahr SM, Tyler BC, Wooldridge N, Butcher BD, Burns TL, Teesch LM, et al. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl Psychiatry. 2015;5:e652.

139.Flowers SA, Evans SJ, Ward KM, et al. Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort. Pharmacother J Hum Pharmacol Drug Ther. 2017;37:261-7.

140.Cani PD, de Vos WM. Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila. Front Microbiol. 2017;8:1765.

141.Yuan X, Zhang P, Wang Y, Liu Y, Li X, Kumar B

引用本文

Laura N. Castellani,Kenya A. Costa-Dookhan,William B. McIntyre,David C. Wright,Stephanie A. Flowers,Margaret K.Hahn*,Kristen M. Ward. Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism, Journal of Psychiatry and Brain Science. 2019; 4; (4). https://doi.org/10.20900/jpbs.20190013.

文献评论

相关学者

相关机构